Apellis Pharmaceuticals, Inc. (APLS)

Apellis Pharmaceuticals' stock price has been impacted by several events in the past six months. The Q2 2025 earnings report showed revenues of $199.7 million with a net loss of $37.7 million. EMPAVELI received FDA approval for C3G and primary IC-MPGN. The Q3 2025 earnings report indicated a significant increase in total revenue to $458.6 million, resulting in a net income of $215.7 million, but APLS shares declined by 31.0% the day after earnings. Analyst ratings were adjusted by Mizuho, JPMorgan Chase & Co., HC Wainwright, and Wall Street Zen. Apellis announced 5-year GALE data for SYFOVRE, showing delayed progression of Geographic Atrophy. The Committee for Medicinal Products for Human Use issued a negative opinion on the marketing authorization application of SYFOVRE for geographic atrophy in Europe, which was confirmed in late 2024.

Specific demand seasonality for Apellis Pharmaceuticals' products is not readily available in the provided search results. Demand for specialized biopharmaceutical products targeting rare diseases or chronic conditions may exhibit less pronounced seasonality compared to consumer goods. Factors like new approvals, clinical trial results, and market access initiatives are likely to be more significant drivers of demand than traditional seasonal patterns.

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutic compounds that modulate the complement system. Its major products include SYFOVRE, the first FDA-approved treatment for geographic atrophy secondary to age-related macular degeneration; EMPAVELI, approved for paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy, and immune complex membranoproliferative glomerulonephritis; and Aspaveli, marketed in the European Union, Japan, and the United Kingdom for PNH. Apellis also has a pipeline of investigational therapies and is exploring RNA therapies, gene-edited FcRn therapy, gene-edited complement therapies, and oral complement inhibitors.

Apellis Pharmaceuticals, Inc. has a global presence with its headquarters in Waltham, Massachusetts, USA. The company operates in the United States, Australia, and Switzerland. Systemic pegcetacoplan is also approved and marketed in Japan, Saudi Arabia, the United Kingdom, and the European Union. Apellis has established a hub in the Greater Zurich Area, Switzerland, for its non-U.S. activities. Other operational locations include Germany, France, Ireland, the Netherlands, Austria, and the Cayman Islands.

Apellis Pharmaceuticals' brand reputation has been influenced by positive developments and ongoing challenges. The company has celebrated achievements such as the FDA approval of EMPAVELI for C3G and IC-MPGN and SYFOVRE's market leadership, but concerns have been noted regarding SYFOVRE's revenue due to free drug programs and operational challenges in patient access. Reports of rare cases of occlusive retinal vasculitis associated with Syfovre and the negative opinion from the European Medicines Agency's CHMP regarding SYFOVRE for GA in Europe have also posed reputational challenges. As of late November 2025, the company's news sentiment score is neutral.

Apellis Pharmaceuticals' ownership is predominantly institutional, with institutional investors holding a significant majority of the company's stock. Major institutional owners include Avoro Capital Advisors LLC, Vanguard Group Inc, Morgan Stanley, Wellington Management Group Llp, Deep Track Capital, LP, BlackRock, Inc., VGHCX - Vanguard Health Care Fund Investor Shares, Aqr Capital Management Llc, Jennison Associates Llc, and State Street Corp. Individual investors hold approximately 10% to 22.27% of the stock, while insiders hold about 3.17% to 6.50% of the shares. Co-Founder and CEO Cedric Francois directly owns about 1.13% to 1.4% of the company's shares.